WHO ICTRP trial
A multicenter randomized phase III study to compare the combination trastuzumab…
NL-OMON41586 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON41586 |
|---|---|
| Public title | A multicenter randomized phase III study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) |
| Scientific title | A multicenter randomized phase III study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) - Pherexa |
| Primary sponsor | Covance |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | The Netherlands |
| Conditions | breast cancer;10006291;breast cancer |
| Interventions | Patients will be randomized in a 1:1 ratio to one of two arms: Arm A: trastuzumab + capecitabine Arm B: pertuzumab + trastuzumab + capecitabine Study drugs will be administered in 3-weekly cycles Pertuzumab: Patients randomized to arm B… |
| Registration date | Apr 7, 2015 |
| Target size | 4 |
| Secondary IDs | 2008-006801-17;NL29687.029.10 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: